Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | KHK | P50053 | 2/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL907485 | 1.00 | KIT (0.41) | KITHRH4PIM1PIM3PIM2 | |
| SCHEMBL20135325 | 0.85 | KIT (0.43) | KITHRH4PIM1PIM3PIM2 | |
| SCHEMBL20134990 | 0.85 | KIT (0.43) | KITHRH4PIM1PIM3PIM2 | |
| SCHEMBL29688471 | 0.85 | KIT (0.43) | KITHRH4PIM1PIM3PIM2 | |
| SCHEMBL20135002 | 0.85 | KIT (0.43) | KITHRH4PIM1PIM3PIM2 | |
| SCHEMBL907759 | 0.84 | HRH4 (0.45) | KITHRH4PIM1PIM3PIM2 | |
| SCHEMBL907761 | 0.84 | HRH4 (0.45) | KITHRH4PIM1PIM3PIM2 | |
| Hydrochloric Acid SCHEMBL29688550 | 0.84 | KIT (0.42) | KITHRH4PIM1PIM3PIM2 | |
| SCHEMBL2366907 | 0.82 | HRH4 (0.48) | HRH4 | |
| SCHEMBL4920049 | 0.79 | HDAC1 (0.42) | KITHRH4PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-1786800-B1 | 1,4-Diarylpiperazine derivatives as capsaicin receptor modulators for treating pain | NEUROGEN CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334382-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1824490-A4 | PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORP (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| CN-101080228-A | Piperazinyl-pyridine analogues | NEUROGEN CORP (US) | 2007-11-28 | — | — | CN | disclosed |
| EP-1824490-A1 | PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1786800-A2 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006065872-A1 | PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2006-06-08 | — | — | US | disclosed |
| WO-2006026135-A2 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | GPR88, PIGO, PRLHR | KIT 143/4885HRH4 31/4885PIM1 3701/4885 |
| US-20060122394-A1 | Substituted biaryl piperazinyl-pyridine analogues | GPR88, PRLHR, GPR68 | KIT 156/4885HRH4 30/4885PIM1 3768/4885 |
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | PRLHR, GPR27, GPR68 | KIT 147/4885HRH4 16/4885PIM1 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.